Subscribe To

Price Alert Latest News Economic Calendar News

STIM / Neuronetics Posts Better Than Expected Q4 Results Despite Lower NeuroStar Therapy System Sales

Neuronetics Inc (NASDAQ: STIM) reported Q4 FY21 sales of $15.02 million, down 4% Y/Y, exceeding previously issued guidance of $13.0 million - $14.0 million and the consensus of $14.43 million. U.S. revenue decreased by 3% during the quarter, and international revenue decreased by 13% Y/Y. Read More

Demo Live Account See Partner Details

Content Topics

Neuronetics

Posts

Better

Than

Expected

Results

Despite

Lower

Neurostar

Therapy

System

Stock

STIM

Posted: Mar 8 2022, 15:16

Author Name: Benzinga

STIM News

By Seeking Alpha
September 6, 2023

Neuronetics: Large Losses May Be Repelling Investors

Neuronetics is currently facing challenges from increased competition and a difficult macro environment, which is impacting growth and profitability.

By Seeking Alpha
August 8, 2023

Neuronetics, Inc. (STIM) Q2 2023 Earnings Call Transcript

Neuronetics, Inc. (NASDAQ:STIM ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 PM ET Company Participants Mark Klausner - ICR Westwicke Keith S

By Seeking Alpha
May 13, 2023

Neuronetics, Inc. (STIM) Q1 2023 Earnings Call Transcript

Neuronetics, Inc. (NASDAQ:STIM ) Q1 2023 Earnings Conference Call May 13, 2023 8:30 AM ET Company Participants Mark Klausner - ICR Westwicke Keith Sul

By GlobeNewsWire
May 9, 2023

Neuronetics to Present at the JMP Securities Life Sciences Conference

MALVERN, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “company” or Neuronetics”) a commercial stage medical techn

By 24/7 Wall Street
March 23, 2023

Cannell Capital Now Owns 11.03% of Neuronetics

Fintel reports that Cannell Capital has filed a 13D/A form with the SEC disclosing ownership of 3.13MM shares of Neuronetics Inc (STIM).

By Zacks Investment Research
March 7, 2023

Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates

Neuronetics (STIM) delivered earnings and revenue surprises of 30.23% and 9.76%, respectively, for the quarter ended December 2022. Do the numbers hol

By GlobeNewsWire
February 22, 2023

Neuronetics to Report Fourth Quarter 2022 Financial and Operating Results and Host Conference Call

MALVERN, Pa., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing,

By Seeking Alpha
February 17, 2023

Why I Am Passing On BrainsWay And Neuronetics

I am bullish on the niche industry that uses magnetic stimulation for brain therapies. BrainsWay and Neuronetics are US-listed stocks in this niche, h

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.